© 2015 by the authors; licensee MDPI, Basel, Switzerland. Selection of inhibitor-resistant viral mutants is universal for viruses that display quasi-species dynamics, and hepatitis C virus (HCV) is no exception. Here we review recent results on drug resistance in HCV, with emphasis on resistance to the newly-developed, directly-acting antiviral agents, as they are increasingly employed in the clinic. We put the experimental observations in the context of quasi-species dynamics, in particular what the genetic and phenotypic barriers to resistance mean in terms of exploration of sequence space while HCV replicates in the liver of infected patients or in cell culture. Strategies to diminish the probability of viral breakthrough during treatment are briefly outlined.
- Antiviral treatment
- Hepatitis C virus
- Viral quasi-species
- Viral resistance
Perales, C., Quer, J., Gregori, J., Esteban, J. I., & Domingo, E. (2015). Resistance of hepatitis C virus to inhibitors: Complexity and clinical implications. Viruses, 7(11), 5746-5766. https://doi.org/10.3390/v7112902